Unknown

Dataset Information

0

Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.


ABSTRACT: Current influenza A virus vaccines do not generate significant immunity against serologically distinct influenza A virus subtypes and would thus be ineffective in the face of a pandemic caused by a novel variant emerging from, say, a wildlife reservoir. One possible solution would be to modify these vaccines so that they prime cross-reactive CD8(+) cytotoxic T lymphocytes (CTL) cell-mediated immunity directed at conserved viral epitopes. A further strategy is to use novel adjuvants, such as the immunomodulatory glycolipid alpha-galactosylceramide (alpha-GalCer). We show here that giving alpha-GalCer with an inactivated influenza A virus has the paradoxical effect of diminishing acute CTL immunity via natural killer T (NKT) cell-dependent expression of indoleamine 2,3-dioxygenase (IDO), an important mediator of immune suppression, while at the same time promoting the survival of long-lived memory CTL populations capable of boosting protection against heterologous influenza A virus challenge. This enhancement of memory was likely due to the alpha-GalCer-induced upregulation of prosurvival genes, such as bcl-2, and points to the potential of alpha-GalCer as an adjuvant for promoting optimal, vaccine-induced CD8(+) T cell memory.

SUBMITTER: Guillonneau C 

PROVIDER: S-EPMC2651345 | biostudies-literature | 2009 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.

Guillonneau Carole C   Mintern Justine D JD   Hubert François-Xavier FX   Hurt Aeron C AC   Besra Gurdyal S GS   Porcelli Steven S   Barr Ian G IG   Doherty Peter C PC   Godfrey Dale I DI   Turner Stephen J SJ  

Proceedings of the National Academy of Sciences of the United States of America 20090211 9


Current influenza A virus vaccines do not generate significant immunity against serologically distinct influenza A virus subtypes and would thus be ineffective in the face of a pandemic caused by a novel variant emerging from, say, a wildlife reservoir. One possible solution would be to modify these vaccines so that they prime cross-reactive CD8(+) cytotoxic T lymphocytes (CTL) cell-mediated immunity directed at conserved viral epitopes. A further strategy is to use novel adjuvants, such as the  ...[more]

Similar Datasets

| S-EPMC5555299 | biostudies-other
| S-EPMC8057254 | biostudies-literature
| S-EPMC1613227 | biostudies-literature
| S-EPMC8551669 | biostudies-literature
| S-EPMC7912564 | biostudies-literature
| S-EPMC3386939 | biostudies-literature